Abstract
Langerhans’ cell histiocytosis (LCH) is a rare condition of uncertain aetiology characterised by the infiltration of certain organs by cells of Langerhans’ cell phenotype (‘LCH cells’), together with inflammatory cells. Tissue damage and fibrosis may ensue, perhaps mediated by cytokines produced by the ‘LCH cells’ or inflammatory cells (or both) and sometimes leading to long term sequelae after the disease has ‘burnt out’. LCH may present to a variety of specialists since many different organs can be involved but the oncologist has traditionally played a major part in management because cytotoxic agents are used for many patients with the disorder. However LCH is not at the present time regarded as a true malignancy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Lichtenstein L. Histiocytosis X. Integration of esoinophilic granuloma of bone, ‘Letterer-Siwe disease’, and’ schuller-Christian disease’ as related manifestations of a single nosologic entity. AMA Arch Pathol 1953; 56:84–102.
Nezelof C, Basset F, Rousseau MF. Histiocytosis X; histogenic argument for a Langerhans’ cell origin. Biomedicine 1973; 18:365–71.
Clinical Writing Group of the Histiocyte Society: Broadbent V, Gadner H, Komp DM et al. Histiocytosis syndromes in children: II. Approach to the clinical and laboratory evaluation of children with Langerhans’ cell histiocytosis. Med Pediatr Oncol 1989; 17:492–5.
Pritchard J, Malone M. Histiocyte disorders:1878–1886. In Peckham M, Pinedo HM, Veronesi U (eds): Oxford Textbook of Oncology. Oxford: Oxford University Press 1995.
Writing Group of the Histiocyte Society: Chu T, D’Angio GJ, Favara B et al. Histiocytosis syndromes in children. Lancet 1987; 1:208–9.
Dunger DB, Broadbent V, Yeoman L et al. The frequency and natural history of diabetes insipidus in children with Langerhans’ cell histiocytosis. N Engl J Med 1989; 321:1157–62.
Grois N, Tsunematsu Y, Barkovich AJ et al. Central nervous system disease in Langerhans’ cell histiocytosis. Br J Cancer 1994; 70 (Suppl XXIII): S24–8.
Egeler RM, Schipper ME, Heymans HSA. Gastrointestinal involvement in Langerhans’ cell histiocytosis (Histiocytosis X): A clinical report of three cases. Eur J Pediatr 1990; 149:325–9.
McLelland J, Broadbent V, Yeomans E et al. Langerhans’ cell histiocytosis: The case for conservative treatment. Arch Dis Child 1990; 65:301–3.
Komp DM, El Mahdi A, Starling KA et al. Quality of survival in Histiocytosis X: A Southwest Oncology Group Study. Med Pediatr Oncol 1980; 8:35–40.
Ceci A, De Terlizzi M, Colella R et al. Langerhans’ cell histiocytosis in childhood: Results from the Italian cooperative AIEOP-CNR-H.X ‘83 study. Med Pediatr Oncol 1993; 21:259–64.
Broadbent V, Pritchard J. Histiocytosis X — current controversies. Arch Dis Child 1985; 60:605–7.
Egeler RM, Thompson RC, Voute PA et al. Intralesional infiltration of corticosteroids in localized Langerhans’ cell histiocytosis. J Pediatr Orthop 1993; 12:811–4.
Sheehan MP, Atherton DJ, Broadbent V et al. Topical nitrogen mustard: An effective treatment for cutaneous Langerhans’ cell histiocytosis. J Pediatr 1991; 119:317–21.
Neumann C, Kolde G, Bonsmann G. Histiocytosis X in an elderly patient. Ultrastructure and immunochemistry after PUVA photochemotherapy. Br J Dermat 1988; 119:385–91.
Willman CL, Busque L, Griffith BB et al. Langerhans’ cell histiocytosis (Histiocytosis X): A clonal proliferative disease. N Engl J Med 1994; 331:154–60.
Yu RC, Chu C, Buluwela L et al. Clonal proliferation of Langerhans’ cells in Langerhans’ cell histiocytosis. Lancet 1994; 343:767–8.
Ceci A, De Terlizzi M, Collela R et al. Etoposide in recurrent Langerhans’ cell histiocytosis: An Italian cooperative study. Cancer 1988; 62:2528–31.
Broadbent V, Pritchard J, Yeomans E. Etoposide (VP16) in the treatment of multisystem Langerhans’ cell histiocytosis (Histiocytosis X). Med Pediatr Oncol 1989; 17:97–100.
Gadner H, Heitger A, Grois N et al. A treatment strategy for disseminated Langerhans’ cell histiocytosis. Med Pediatr Oncol 1994; 23:72–80.
Ladisch S, Gadner H. Treatment of Langerhans’ cell histiocytosis — evolution and current approaches. Br J Cancer 1994; 70 (Suppl XXIII): S41–6.
Mahmoud HH, Wang WC, Murphy SB. Cyclosporin therapy for advanced Langerhans’ cell histiocytosis. Blood 1991; 77:721–5.
Kelly KM, Beverley PC, Chu AC et al. Successful in vivo localization of Langerhans’ cell histiocytosis with use of a monoclonal antibody, NA1/34. J Pediatr 1994; 125:717–22.
Morgan G. Myeloablative therapy and bone marrow transplantation for Langerhans’ cell histiocytosis. Br J Cancer 1994; 70 (Suppl XXIII): S52–3.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Craze, J.L., Pritchard, J. (1997). Langerhans’ cell histiocytosis: A case history. In: Souhami, R.L. (eds) The Teaching Cases from Annals of Oncology. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5456-7_14
Download citation
DOI: https://doi.org/10.1007/978-94-011-5456-7_14
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-4117-8
Online ISBN: 978-94-011-5456-7
eBook Packages: Springer Book Archive